Category

UF Startup

New OxThera/Oxabact US Patent Granted

UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces that a new US patent has been granted for its product candidate Oxabact and a method for the treatment or prevention of an oxalate-related disorder, such as hyperoxaluria.

Plasma Oxalate and Kidney Function Are Correlated in Patients With Primary Hyperoxaluria With Maintained Kidney Function – Data From Three Placebo-Controlled Studies Published

UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces the publication of an article in Pediatric Nephrology, on the significant correlation between plasma oxalate and kidney function in three controlled clinical trials with PH patients.

AbFero Pharmaceuticals Announces Funding From Cure Parkinson’s for Lead Compound SP-420

AbFero Ltd., a subsidiary of UF startup AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, announced the award of a grant from Cure Parkinson's for the development of their lead, brain-penetrant iron chelating agent, SP-420, as a disease modifying therapy for Parkinson's disease (PD).